Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis.
Saved in:
| Title: | Ocrelizumab modulates the IL-2 signaling pathway and associated lncRNAs in multiple sclerosis. |
|---|---|
| Authors: | Rangani F; Department of Clinical Neuroscience, Karolinska Institutet, and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Medical Biotechnology and Nanotechnology, Mashhad University of Medical sciences, Mashhad, Iran., Nahayati MA; Department of Neurology and Rehabilitation, Waddell Center for Multiple Sclerosis, Cincinnati University, OH, USA., Pahlevan Kakhki M; Department of Clinical Neuroscience, Karolinska Institutet, and Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden. Electronic address: Majid.Pahlevan.kakhki@ki.se., Aghaee-Bakhtiari SH; Bioinformatics Research Center, Basic Sciences Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.. Electronic address: aghaeibh@mums.ac.ir. |
| Source: | Journal of the neurological sciences [J Neurol Sci] 2026 Jan 15; Vol. 480, pp. 125693. Date of Electronic Publication: 2025 Dec 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 0375403 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-5883 (Electronic) Linking ISSN: 0022510X NLM ISO Abbreviation: J Neurol Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
